Recombinant Human SMARCA4 protein, His-tagged

• Cat.No.: SMARCA4-5521H
• Product Overview: Recombinant Human SMARCA4 protein(P51532)(700-1246aa), fused to N-terminal His tag, was expressed in Yeast.

Specification

• Source: Yeast
• Species: Human
• Tag: His
• Form: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
• Molecular Mass: 64.8 kDa
• Protein length: 700-1246aa
• Purity: Greater than 90% as determined by SDS-PAGE.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Reconstitution: Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%.

Gene Information

• Gene Name: SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 [ Homo sapiens ]
• Official Symbol: SMARCA4
• Synonyms: SMARCA4; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; SNF2L4; transcription activator BRG1; ATP dependent helicase SMARCA4; BAF190; brahma protein like 1; BRG1; BRM/SWI2 related gene 1; FLJ39786; global transcription activator homologous sequence; homeotic gene regulator; hSNF2b; mitotic growth and transcription activator; nuclear protein GRB1; SNF2; SNF2 BETA; SNF2 like 4; SNF2LB; sucrose nonfermenting like 4; SWI2; BAF190A; SNF2-like 4; protein BRG-1; brahma protein-like 1; BRM/SWI2-related gene 1; protein brahma homolog 1; BRG1-associated factor 190A; sucrose nonfermenting-like 4; ATP-dependent helicase SMARCA4; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4; RTPS2; SNF2-BETA
• Gene ID: 6597
• mRNA Refseq: NM_001128844
• Protein Refseq: NP_001122316
• MIM: 603254
• UniProt ID: P51532

Reviews

02/18/2023

The SMARCA4 protein offers exceptional quality that meets the rigorous demands of experimental research.

11/01/2018

It exhibits exceptional performance in ELISA assays, making it an excellent choice for researchers studying angiopoietins, angiogenesis, or vascular biology.

10/30/2016

Its purity, consistency, and reliable performance make it a top choice for a wide range of applications.

Q&As

Can epigenetic therapies target SMARCA4 alterations?

Epigenetic therapies that modulate gene expression could indirectly affect SMARCA4-altered cancers, though specific targeting remains a challenge.

Are there diagnostic tests for SMARCA4 mutations?

Yes, there are genetic tests available to identify SMARCA4 mutations in tumors, aiding in prognosis and treatment decisions.

Are there ongoing clinical trials focusing on SMARCA4 alterations?

Yes, there are clinical trials exploring new treatment strategies for SMARCA4-altered cancers, aiming to improve patient outcomes.

Is SMARCA4 solely associated with cancer?

No, SMARCA4's functions extend beyond cancer and have implications in various biological processes, including development and differentiation.

How can SMARCA4 mutations influence patient prognosis?

Patients with SMARCA4 mutations in their tumors often face a poorer prognosis, which necessitates tailored treatment approaches.